Tissue-type plasminogen activator's 10% one-year edge
In this trial, 41,021 acute myocardial infarction patients were randomized to one of four thrombolytic regimens. Patients who received accelerated tissue-type plasminogen activator had a significantly lower one- year mortality rate (9.1%) than those who received streptokinase with subcutaneous heparin (10.1%), streptokinase with intravenous heparin (10.1%), or combination plasminogen activator and streptokinase therapy (9.9%). Translating the results into lives saved shows that the use of accelerated tissue-type plasminogen activator can save 10 more lives per 1,000 patients treated than streptokinase regimens.
Williams, PA; Califf, RM; Topol, EJ
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)